BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1460286)

  • 1. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages.
    Ambrosino DM; Bolon D; Collard H; Van Etten R; Kanchana MV; Finberg RW
    J Immunol; 1992 Dec; 149(12):3978-83. PubMed ID: 1460286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
    Donnelly JJ; Deck RR; Liu MA
    J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation.
    Sood SK; Daum RS
    Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Wong VK; Quagliata R; Adler R; Kim KS
    Am J Dis Child; 1991 Jul; 145(7):742-5. PubMed ID: 2058604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
    Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
    Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro induction of a Haemophilus influenzae type b polysaccharide-specific antibody response in human peripheral blood lymphocytes of individuals recently vaccinated with an oligosaccharide-protein conjugate.
    Peeters CC; Tenbergen-Meekes AM; Heijnen CJ; Poolman JT; Zegers BJ; Rijkers GT
    J Immunol; 1991 Dec; 147(12):4192-9. PubMed ID: 1753096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
    Santosham M; Wolff M; Reid R; Hohenboken M; Bateman M; Goepp J; Cortese M; Sack D; Hill J; Newcomer W
    N Engl J Med; 1991 Jun; 324(25):1767-72. PubMed ID: 1903846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine (PedvaxHIB) in Papua New Guinean children.
    Lehmann D; Kakazo M; Yarsley S; Javati A; Taime J; Saleu G; Namuigi P; Alpers MP; Mendelman PM; Staub T
    P N G Med J; 1998; 41(3-4):102-11. PubMed ID: 10934551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age.
    Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P
    Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
    Tarkowski A; Lue C; Moldoveanu Z; Kiyono H; McGhee JR; Mestecky J
    J Immunol; 1990 May; 144(10):3770-8. PubMed ID: 2110213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH
    Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
    Vella PP; Staub JM; Armstrong J; Dolan KT; Rusk CM; Szymanski S; Greer WE; Marburg S; Kniskern PJ; Schofield TL
    Pediatrics; 1990 Apr; 85(4 Pt 2):668-75. PubMed ID: 2107517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.